Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine −

VVT Med Provides Update on Management Cease Trade Order

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

By The Northwire Desk — AI Analysis Jun 12, 2026 · 17:00 VVTM · 0.22 VVT Med Inc.
Executive Summary
  • VVT Med Inc. issued a bi-weekly status update regarding a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission (BCSC).
  • The MCTO was originally issued due to continuous disclosure defaults, specifically the delay in filing audited financial statements for the fiscal year ended December 31, 2025.
  • The company anticipates filing the overdue FYE 2025 audited financials and Q1 2026 interim financials by June 29, 2026.
  • The MCTO restricts trading by the CEO and CFO and limits corporate securities transactions with insiders until all required filings are submitted.
  • The company confirms no material changes to prior default announcements and no undisclosed material information.
Material Impact
  • The news is a routine compliance update that confirms the previously communicated June 29, 2026 filing deadline.
  • It does not introduce new commercial catalysts, financial results, or strategic shifts.
  • The MCTO remains in effect, continuing to restrict insider trading and limiting the company's ability to issue securities to insiders/employees, which constrains near-term capital flexibility.
  • Commercial activities (distribution agreements in Italy, Dominican Republic, and US) are proceeding independently, but the regulatory overhang persists without resolution.
VVTM · Price
Company Overview
  • VVT Med Inc. is a medical device company focused on the development and commercialization of the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) solution for treating venous disease (varicose veins).
  • The technology enables controlled sclerosant delivery with simultaneous blood aspiration, eliminating the need for thermal energy or tumescent anesthesia.
  • The company is pursuing a global commercialization strategy through exclusive distribution partnerships, having secured agreements in India, Italy, the Dominican Republic, and the U.S. (via Northwell Health).
  • The company is listed on the TSX Venture Exchange and is in the early stages of scaling its commercial operations.
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory